BioLight Reports Second Quarter 2015 Financial Results

BioLight today reported operational and financial results for the second quarter ended June 30, 2015.

Operational Highlights:

  • Completed an upsized private investment and signed a strategic partnership with Rock-One International Holdings Ltd. designed to help BioLight maximize its presence within China, the second largest healthcare market in the world after the U.S.
  • Signed a collaboration agreement with Ora, Inc., a world-leading independent, full-service ophthalmic contract research organization and product development firm, pursuant to which the companies will work together to advance the clinical, regulatory and commercial development of its TeaRx™ multi-parameter diagnostic test for dry eye syndrome (DES).
  • Reported first IOPtiMate™ System sales in new territories as well as the first sale of the IOPtiMate™ system procedures.
  • Obtained CE Marking for the CellDetect® non-invasive test for detecting bladder cancer in urine, enabling the product to be marketed and sold in Europe and other territories.
  • Subsequent to the end of Q2, reported positive clinical study results for the identification of new genetic markers to predict risk of developing BRONJ.

Link to complete article

Link to Q2-2015 financial results

 

Link to Newsroom

Comments are closed